Welcome to our dedicated page for Nexalin Tech news (Ticker: NXLIW), a resource for investors and traders seeking the latest updates and insights on Nexalin Tech stock.
Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) generates news centered on its non-invasive, frequency-based neurostimulation devices and their application in mental health and neurological disorders. News coverage for Nexalin often highlights developments related to its proprietary Deep Intracranial Frequency Stimulation (DIFS™) platform, including clinical data, regulatory milestones, and international commercialization activities.
Investors and followers of Nexalin’s news can expect updates on peer-reviewed studies involving the company’s technology in conditions such as Alzheimer’s disease, dementia, attention deficit hyperactivity disorder (ADHD), and gambling disorder with alcohol use disorder comorbidity. Recent announcements have described randomized, sham-controlled trials and case reports that examine changes in cognition, attention, and brain network function using tools like EEG, MEG, and functional MRI, as well as reported safety and tolerability outcomes.
Nexalin’s news flow also includes regulatory and strategic updates, such as Q-Submission interactions with the U.S. Food and Drug Administration for the Gen-2 SYNC™ console in Alzheimer’s disease, acceptance of FDA filings, and discussions of potential De Novo pathways. Internationally, the company reports on regulatory approvals in markets including China, Brazil, Oman, and Israel, along with distribution agreements like its exclusive partnership with Carmi Masha Technologies Ltd. in Israel.
Additional coverage may feature corporate events, investor webinars, conference participation, and Scientific Advisory Board appointments that relate to Nexalin’s focus on mental health, Alzheimer’s disease, and traumatic brain injury research. For users tracking NXLIW and NXL, this news page offers a centralized view of clinical, regulatory, and corporate developments that shape Nexalin’s progress in the neurostimulation and mental health space.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) provided a business update on March 27, 2023, highlighting progress in clinical trials for new neurostimulation devices aimed at treating mental health disorders. The Gen-2 and Gen-3 devices are expected to improve treatment efficacy without medication. Revenue for 2022 reached $1.3 million, a significant increase from $0.1 million in 2021, primarily due to more device sales. While operating expenses decreased to $2.8 million from $6.1 million, the net loss narrowed to $1.7 million per share. The company reports having $7.0 million in liquidity for future operations.
Nexalin Technology announced the appointment of Michael Nketiah as Senior Vice President of Quality, Clinical, and Regulatory. Nketiah brings over 23 years of experience in regulatory affairs and clinical operations, specifically with the FDA. His expertise will support the company in accelerating FDA clearance for its Generation 2 and Generation 3 neurostimulation devices, aimed at improving healthcare outcomes for mental and neurodegenerative illnesses. The Gen-2 device is designed to penetrate deeper into the brain using an advanced waveform, while the Gen-3 prototype will utilize a virtual-clinic model for treatment.
Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) provided a business update emphasizing its advancements in neurostimulation devices aimed at combating mental health disorders. The company is enhancing its Gen-1 device to a more powerful Gen-2 model with a waveform increase from 4 milliamps to 15 milliamps, expected to improve treatment efficacy. Plans for FDA submissions and clinical trials are outlined, including a strategy for addressing Major Depressive Disorder. Additionally, Nexalin reports progress with its devices in China and a recent white paper supporting its technology's effectiveness for anxiety treatment.
Nexalin Technology, Inc. (NXL, NXLIW) announced positive results from a white paper published by the Second Xiangya Hospital, documenting the effectiveness of its tACS device for treating generalized anxiety disorder. The study reported complete disappearance of somatic anxiety symptoms and improved sleep quality in a patient after a 10-day treatment regimen. The benefits persisted for four months, indicating the device's potential in addressing mental health issues without side effects. The company aims to expand its clinical research and treatment applications in the mental health field.